Jeff Glasgow

Jeff Glasgow

Auto-generated profile, based on publicly available information

Jeff Glasgow

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AGAnum Glasgow
Anum Glasgow
JGJeff Glasgow
Jeff Glasgow
Daniel LimontaDaniel Limonta
Daniel Limonta
PSPaige Solomon
Paige Solomon
ILIrene Lui
Irene Lui
JWJames A. Wells
James A. Wells
Significance: During the ongoing COVID-19 pandemic, protein engineering offers a rapid and powerful approach for building therapeutics to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. We use computational design, affinity maturation, and fusion to dimerization domains to engineer “receptor traps” based on wild-type angiotensin-converting enzyme II (ACE2), the target for viral spike-mediated SARS-CoV-2 entry into cells. The optimized ACE2 receptor traps neutralize authentic SARS-CoV-2 infections as effectively as high-affinity antibodies isolated from convalescent patients and also bind viral spike proteins from other coronaviruses known to cause respiratory diseases. ACE2 receptor traps have large binding interfaces and block the entire receptor binding interface, limiting the potential impact of viral escape mutations.

28 October 2020 in mSphere
Verified
Journal Article
Open access
PDF file
JBJames R. Byrnes
James R. Byrnes
XZXin X. Zhou
Xin X. Zhou
ILIrene Lui
Irene Lui
SESusanna K. Elledge
Susanna K. Elledge
JGJeff E. Glasgow
Jeff E. Glasgow
JWJames A. Wells
James A. Wells
With the emergence and continued spread of the SARS-CoV-2 virus, and of the associated disease, coronavirus disease 2019 (COVID-19), there is an urgent need for improved understanding of how the body mounts an immune response to the virus. Here, we developed a competitive SARS-CoV-2 serological assay that can simultaneously determine whether an individual has developed antibodies against the SARS-CoV-2 Spike protein receptor-binding domain (RBD) and measure the proportion of these antibodies that block interaction with the human angiotensin-converting enzyme 2 (ACE2) required for viral entry. Using this assay and 144 SARS-CoV-2 patient serum samples, we found that a majority of anti-RBD antibodies compete for ACE2 binding. These results not only highlight the need to design vaccines to generate such blocking antibodies but also demonstrate the utility of this assay to rapidly screen patient sera for potentially neutralizing antibodies.

31 January 2022 in Cell Chemical Biology
Verified
Journal Article
Closed access
JGJeff E. Glasgow
Jeff E. Glasgow
JBJames R. Byrnes
James R. Byrnes
SBSusannah D. Barbee
Susannah D. Barbee
JMJoshua M. Moreau
Joshua M. Moreau
MRMichael D. Rosenblum
Michael D. Rosenblum
JWJames A. Wells
James A. Wells

1 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAnum Glasgow
Anum Glasgow
JGJeff Edward Glasgow
Jeff Edward Glasgow
Daniel LimontaDaniel Limonta
Daniel Limonta
PSPaige Solomon
Paige Solomon
ILIrene Lui
Irene Lui
JWJames A. Wells
James A. Wells
An essential mechanism for SARS-CoV-1 and -2 infection begins with the viral spike protein binding to the human receptor protein angiotensin-converting enzyme II (ACE2). Here we describe a stepwise engineering approach to generate a set of affinity optimized, enzymatically inactivated ACE2 variants that potently block SARS-CoV-2 infection of cells. These optimized receptor traps tightly bind the receptor binding domain (RBD) of the viral spike protein and prevent entry into host cells. We first computationally designed the ACE2-RBD interface using a two-stage flexible protein backbone design process that improved affinity for the RBD by up to 12-fold. These designed receptor variants were affinity matured an additional 14-fold by random mutagenesis and selection using yeast surface display. The highest affinity variant contained seven amino acid changes and bound to the RBD 170-fold more tightly than wild-type ACE2. With the addition of the natural ACE2 collectrin domain and fusion to a human Fc domain for increased stabilization and avidity, the most optimal ACE2 receptor traps neutralized SARS-CoV-2 pseudotyped lentivirus and authentic SARS-CoV-2 virus with half-maximal inhibitory concentrations (IC50) in the 10-100 ng/ml range. Engineered ACE2 receptor traps offer a promising route to fighting infections by SARS-CoV-2 and other ACE2-utilizing coronaviruses, with the key advantage that viral resistance would also likely impair viral entry. Moreover, such traps can be pre-designed for viruses with known entry receptors for faster therapeutic response without the need for neutralizing antibodies isolated or generated from convalescent patients.

10 January 2025 in Science Advances
Verified
Journal Article
Open access
DRDaniel Rabe
Daniel Rabe
ACAdarsh Choudhury
Adarsh Choudhury
DLDasol Lee
Dasol Lee
ELEvelyn G. Luciani
Evelyn G. Luciani
UHUyen K. Ho
Uyen K. Ho
SSShannon Stott
Shannon Stott
Measuring virus in biofluids is complicated by confounding biomolecules coisolated with viral nucleic acids. To address this, we developed an affinity-based microfluidic device for specific capture of intact severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach used an engineered angiotensin-converting enzyme 2 to capture intact virus from plasma and other complex biofluids. Our device leverages a staggered herringbone pattern, nanoparticle surface coating, and processing conditions to achieve detection of as few as 3 viral copies per milliliter. We further validated our microfluidic assay on 103 plasma, 36 saliva, and 29 stool samples collected from unique patients with COVID-19, showing SARS-CoV-2 detection in 72% of plasma samples. Longitudinal monitoring in the plasma revealed our device’s capacity for ultrasensitive detection of active viral infections over time. Our technology can be adapted to target other viruses using relevant cell entry molecules for affinity capture. This versatility underscores the potential for widespread application in viral load monitoring and disease management.

21 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
SESusanna K. Elledge
Susanna K. Elledge
XZXin X. Zhou
Xin X. Zhou
JBJames R. Byrnes
James R. Byrnes
AMAlexander J. Martinko
Alexander J. Martinko
ILIrene Lui
Irene Lui
JWJames A. Wells
James A. Wells
SUMMARY: Current serology tests for SARS-CoV-2 antibodies mainly take the form of enzyme-linked immunosorbent assays or lateral flow assays, with the former being laborious and the latter being expensive and often lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost solution-based assay to detect antibodies in serum, plasma, whole blood, and saliva, using rationally designed split luciferase antibody biosensors (spLUC). This new assay, which generates quantitative results in as short as 5 minutes, substantially reduces the complexity and improves the scalability of COVID-19 antibody tests for point-of-care and broad population testing.